SCHEMBL5426580

SCHEMBL5426580

CCCOCCCNC(=O)c1ccc(C)nc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.67
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 2/20 0.54
CYP19A1 P11511 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
GSK3B P49841 1/20 0.52
HPGD P15428 3/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
POLB P06746 2/20 0.51
ALOX15 P16050 1/20 0.51
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
LMNA P02545 1/20 0.50
KMT2A Q03164 3/20 0.49
NAMPT P43490 1/20 0.49
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5422992 0.86 KDM4E (0.74) KDM4ETDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL13450252 0.86 SMN1; SMN2 (0.52) KDM4EALDH1A1SMN1; SMN2HPGDNPC1
SCHEMBL5426967 0.85 KDM4E (0.76) KDM4ETDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL18116704 0.83 KDM4E (0.74) KDM4ETDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL5423478 0.83 KDM4E (0.72) KDM4ETDP1ALDH1A1CYP19A1POLB
SCHEMBL5438583 0.82 KDM4E (0.63) KDM4ETDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL5423126 0.80 KDM4E (0.68) KDM4ETDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL12588233 0.79 KDM4E (0.76) KDM4ETDP1ALDH1A1CYP19A1GSK3B
SCHEMBL1543075 0.79 MAPK14 (0.48) KDM4EALDH1A1SMN1; SMN2HPGDNPC1
SCHEMBL4354408 0.77 NAAA (0.67) TDP1ALDH1A1SMN1; SMN2HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US claimed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP claimed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO claimed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US disclosed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO disclosed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 KDM4E 3402/4885TDP1 4517/4885ALDH1A1 837/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 KDM4E 3402/4885TDP1 4517/4885ALDH1A1 837/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 KDM4E 3429/4885TDP1 4320/4885ALDH1A1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.